The Chief Scientific Adviser to the Department of Health and Social Care visits ieso Digital Health
• Professor Lucy Chappell visited ieso Digital Health headquarters in Cambridge
Cambridge, UK, June 20, 2023 - Professor Lucy Chappell FMedSci, Chief Scientific Adviser to the Department of Health and Social Care and CEO of the National Institute for Health and Care Research, last week visited the Cambridge headquarters of ieso Digital Health, the innovative healthcare company developing AI-driven evidence-based mental health solutions.
Professor Chappell joined ieso’s interdisciplinary team of AI, clinical and cognitive neuroscience experts to discuss how data science and AI, underpinned by a responsible approach to innovation, can shape the future of mental healthcare.
“ieso is transforming psychological therapy for common mental health conditions, focusing on solutions that are accessible to more people, high-quality and clinically effective, and scalable. By innovating responsibly, we can make the UK the global leader in mental healthcare technology” - said Dr Andrew Welchman, Executive Vice President for Impact, ieso Digital Health.
"It was fascinating to learn about ieso's research and its responsible approach to innovation. Discussing the opportunities and challenges of developing and deploying digital mental health tools in the NHS was hugely informative and valuable" said Prof Chappell.
About ieso:
ieso is a data-driven AI healthcare company pioneering next-generation digital therapeutics to improve mental health outcomes and access to care and is developing a pipeline of AI-driven evidence-based mental health assessment tools and solutions to democratise access to mental health therapy at scale.
For over a decade, ieso has delivered text-based cognitive behavioural therapy (CBT) for adults with depression and anxiety disorders through our online therapy platform. With a network of more than 600 fully qualified therapists, they have treated over 110,000 adults in the NHS and delivered over 600,000 therapy hours with excellent patient outcomes and experience.
The company has analysed over 700 million datapoints to decode the active ingredients of therapy to develop scalable digital therapeutics. ieso’s research has been published in several peer-reviewed journals including the Lancet and JAMA, shaping our understanding of scalable digital mental healthcare solutions.
For more information, visit www.iesogroup.com and connect with us on and LinkedIn.
